Name: BI-9321
Brand: TargetMol
SKU: T10538
Rating: 4.5 (1 reviews)

BI-9321

😃Good

Catalog No. T10538Cas No. 2387510-86-1

BI-9321 is a selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist (Kd: 166 nM). BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2.

BI-9321

😃Good

Catalog No. T10538Cas No. 2387510-86-1

BI-9321 is a selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist (Kd: 166 nM). BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2.

Pack Size	Price	Availability
25 mg	$2,100	6-8 weeks
50 mg	$2,730	6-8 weeks
100 mg	$4,350	6-8 weeks

Bulk & Custom

Add to Cart

QWhat’s pIC50?

ApIC50 is the negative log of the IC50 value when converted to molar.That is, pIC50=-log(IC50).

QHow to recommend specific or broad-spectrum inhibitors for a target? What is the difference between specificity and nonspecificity?

AInhibitors can be classified into two types based on specificity: broad-spectrum (pan) and selective inhibitors. Pan inhibitors are inhibitors of a particular target that have inhibitory effects on all subtypes or members of the entire family. Selective inhibitors have particularly high inhibitory rates or specific inhibitory effects on a subtype of a protein kinase or a member of a family of proteins. The evaluation of the inhibitory efficiency of an inhibitor generally relies on the IC50 value, with lower IC50 values indicating higher inhibitory efficiency. We recommend considering the above characteristics comprehensively when selecting inhibitors, and you can also contact our technical team for recommendations on relevant inhibitors.

QWhat’s EC50?

AHalf maximal effective concentratioin(EC50) refers to the concentration of a compound that achieves 50% of the maximum effect(inhibitory/stimulatory effect),after a specified exposure duration.

QWhat’s Kd?

ADissociation consent (Kd) reflects the affinity of a compound for its target. In some cases, it can be equivalent to Ki.

QWhat’s Ki?

AInhibitory consent (Ki) reflects the strength of inhibitor binding to the target, corresponding to the concentration of free inhibitor when 50% of the target is bound by the inhibitor.

Product Introduction

Bioactivity

Description	BI-9321 is a selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist (Kd: 166 nM). BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2.
Targets&IC50	NSD3-PWWP1:(kd)166 nM
In vitro	BI-9321 specifically disrupts histone interactions of the NSD3-PWWP1 domain (IC50: 1.2 μM in U2OS cells). BI-9321 is targeting the methyl-lysine binding site of the PWWP1 domain and cellular target engagement at 1?μM. BI-9321 downregulates Myc messenger RNA expression and reduces proliferation in MOLM-13 cells.

Chemical Properties

Molecular Weight	360.43
Formula	C₂₂H₂₁FN₄
Cas No.	2387510-86-1
Relative Density.	1.24 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.